SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Jul 5, 2012
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: July 5, 2012 · CIK: 0001533040 · Accession: 0001193125-12-294109
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-181534
Letter
Re: RXi Pharmaceuticals Corporation (the “Company”)
Correspondence
July 5, 2012
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-4628
Registration Statement on Form S-1
Filed May 18, 2012
File No. 333-181534
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:00 p.m. (Eastern) on Friday, July 6, 2012, or as soon thereafter as practicable.
In making this acceleration request, the Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
By: RXi Pharmaceuticals Corporation
Show Raw Text
CORRESP 1 filename1.htm Correspondence July 5, 2012 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-4628 Re: RXi Pharmaceuticals Corporation (the “Company”) Registration Statement on Form S-1 Filed May 18, 2012 File No. 333-181534 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:00 p.m. (Eastern) on Friday, July 6, 2012, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, By: RXi Pharmaceuticals Corporation /s/ Geert Cauwenbergh Geert Cauwenbergh, Dr. Med. Sc. President and Chief Executive Officer cc: Ryan Murr, Esq. (Ropes & Gray LLP)